Presurgical Targeted Therapy Delays Relapse of High-Risk Stage 3 Melanoma

Excerpt:

“A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared to standard-of-care surgery for patients with stage 3 disease, researchers at The University of Texas MD Anderson Cancer Center report in Lancet Oncology. Patients who had no sign of disease at surgery after combination treatment did not progress to metastasis.

“Early results of the study comparing surgery to pre- and post-surgical treatment with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib were so strikingly positive that MD Anderson’s data safety monitoring board ordered the randomized, prospective phase II trial halted and changed to a single-arm using the combination.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.